Danish Breast Cancer Group Skagen Trial 1: A report on annual trial participation

被引：0
|
作者：
Thorsen, L. Bech Jellesmark [1 ]
Mjaaland, I. [2 ]
Hjelstuen, M. [2 ]
Jakobsen, E. Hugger [3 ]
Berg, M. [3 ]
Lorincz, T. [4 ]
Jensen, I. [4 ]
Kasti, U. [5 ]
Hasler, M. [5 ]
Nielsen, M. Holck [6 ]
Lorentzen, E. Laugaard [7 ]
Al-Rawi, S. Aziz-Jowad [8 ]
Nielsen, M. M. Bruun [8 ]
Krause, M. [9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ,17 ]
Linge, A. [9 ,10 ,11 ,12 ,13 ,14 ,15 ,16 ,17 ]
Kamby, C. [18 ]
Boye, K. [18 ]
Yates, E. Svitzer [1 ]
Offersen, B. Vrou [1 ,19 ]
机构：
[1] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[2] Stavanger Univ Hosp, Dept Oncol, Stavanger, Norway
[3] Vejle Hosp, Dept Oncol, Vejle, Denmark
[4] Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark
[5] Sorlandet Hosp, Dept Oncol, Kristiansand, Norway
[6] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[7] Odense Univ Hosp, Lab Radiat Phys, Odense, Denmark
[8] Zealand Univ Hosp, Dept Clin Oncol & Palliat Care, Naestved, Denmark
[9] Univ Hosp, Dresden, Germany
[10] Fac Med Carl Gustav Carus, Dresden, Germany
[11] Tech Univ Dresden, Dresden, Germany
[12] German Canc Consortium Dresden, Dresden, Germany
[13] Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany
[14] Natl Ctr Tumor Dis, Dresden, Germany
[15] German Canc Res Ctr, Heidelberg, Germany
[16] Dept Radiat Oncol, Dresden, Germany
[17] OncoRay Ctr, Dresden, Germany
[18] Rigshosp, Dept Oncol, Copenhagen, Denmark
[19] Aarhus Univ Hosp, Dept Expt Clin Oncol, Aarhus, Denmark
来源：
RADIOTHERAPY AND ONCOLOGY | 2022年 / 170卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-0740
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [1] Validating the ESTRO target consensus: pattern of breast cancer failures in the DBCG Skagen trial 1
    Hogsbjerg, Kristine Wiborg
    Thomsen, Mette Skovhus
    Maae, Else
    Berg, Martin
    Nielsen, Mette Holck
    Lorenzen, Ebbe Laugaard
    Maraldo, Maja Vestmo
    Boye, Kristian
    Stenbygaard, Lars
    Jensen, Ingelise
    Al-Rawi, Sami Aziz-Jowad
    Jacobsen, Kirsten Legaard
    Matthiessen, Louise Wichmann
    Andersen, Karen
    Offersen, Birgitte Vrou
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S621 - S624
  • [2] Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial
    Hogsbjerg, Kristine W.
    Maae, Else
    Nielsen, Mette H.
    Stenbygaard, Lars
    Pedersen, Anders N.
    Yates, Esben
    Berg, Martin
    Lorenzen, Ebbe L.
    Jensen, Ingelise
    Josipovic, Mirjana
    Thomsen, Mette S.
    Offersen, Birgitte V.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194
  • [3] Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1
    Francolini, Giulio
    Thomsen, Mette S.
    Yates, Esben S.
    Kirkove, Carine
    Jensen, Ingelise
    Blix, Egil S.
    Kamby, Claus
    Nielsen, Mette H.
    Krause, Mechthild
    Berg, Martin
    Mjaaland, Ingvil
    Schreiber, Andreas
    Kasti, Unn-miriam
    Boye, Kristian
    Offersen, Birgitte V.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 (02) : 282 - 287
  • [4] Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial
    Offersen, Birgitte V.
    Alsner, Jan
    Nielsen, Hanne M.
    Jakobsen, Erik H.
    Nielsen, Mette H.
    Stenbygaard, Lars
    Pedersen, Anders N.
    Thomsen, Mette S.
    Yates, Esben
    Berg, Martin
    Lorenzen, Ebbe L.
    Jensen, Ingelise
    Josipovic, Mirjana
    Jensen, Maj-Britt
    Overgaard, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4189 - +
  • [5] Barriers to minority participation in a breast cancer chemoprevention trial
    Jacobson, JS
    Grann, VR
    Troxel, AB
    Hershman, D
    Karp, J
    Myers, C
    Neugut, AI
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (02) : 409 - 409
  • [6] Assessment of clinical trial participation on breast cancer survival
    Parise, C.
    Caggiano, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [7] EVALUATION OF RADIOTHERAPY IN HIGH-RISK BREAST-CANCER PATIENTS - REPORT FROM THE DANISH-BREAST-CANCER-COOPERATIVE-GROUP (DBCG-82) TRIAL
    OVERGAARD, M
    CHRISTENSEN, JJ
    JOHANSEN, H
    NYBORASMUSSEN, A
    ROSE, C
    VANDERKOOY, P
    PANDURO, J
    LAURSEN, F
    KJAER, M
    SORENSEN, NE
    GADEBERG, CC
    HJELMHANSEN, M
    OVERGAARD, J
    ANDERSEN, KW
    ZEDELER, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (05): : 1121 - 1124
  • [8] TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
    Charlotte Levin Tykjær Jørgensen
    Christina Bjerre
    Bent Ejlertsen
    Karsten D Bjerre
    Eva Balslev
    Annette Bartels
    Nils Brünner
    Dorte L Nielsen
    BMC Cancer, 14
  • [9] TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
    Tykjr Jorgensen, Charlotte Levin
    Bjerre, Christina
    Ejlertsen, Bent
    Bjerre, Karsten D.
    Balslev, Eva
    Bartels, Annette
    Brunner, Nils
    Nielsen, Dorte L.
    BMC CANCER, 2014, 14
  • [10] Acute toxicity after loco regional breast radiation therapy in the randomized DBCG SKAGEN trial 1
    Milo, M. L.
    Lorincz, T.
    Nielsen, M. H.
    Kamby, C.
    Bechmann, T.
    Al-Rawi, S.
    Matthiessen, L. W.
    Krause, M.
    Schreiber, A.
    Mjaaland, I.
    Kasti, U.
    Brix, E. S.
    Kedzierawski, P.
    Marinko, T.
    Kirkove, C.
    Overgaard, J.
    Offersen, B. V.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S747 - S748
12345